ANGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), AngioDynamics's current share price is $5.81. AngioDynamics's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 was $0.47. AngioDynamics's Cyclically Adjusted Price-to-FCF for today is 12.36.
The historical rank and industry rank for AngioDynamics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, AngioDynamics's highest Cyclically Adjusted Price-to-FCF was 50.77. The lowest was 10.83. And the median was 24.17.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
AngioDynamics's adjusted free cash flow per share data for the three months ended in Feb. 2024 was $-0.407. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.47 for the trailing ten years ended in Feb. 2024.
The historical data trend for AngioDynamics's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AngioDynamics Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 22.00 | 16.25 | 15.81 | 13.04 | 11.72 |
For the Medical Instruments & Supplies subindustry, AngioDynamics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where AngioDynamics's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
AngioDynamics's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 5.81 | / | 0.47 | |
= | 12.36 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AngioDynamics's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 is calculated as:
For example, AngioDynamics's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Feb. 2024 (Change) | * | Current CPI (Feb. 2024) |
= | -0.407 | / | 129.4194 | * | 129.4194 | |
= | -0.407 |
Current CPI (Feb. 2024) = 129.4194.
AngioDynamics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201405 | 0.171 | 100.373 | 0.220 |
201408 | 0.003 | 100.352 | 0.004 |
201411 | -0.129 | 99.635 | -0.168 |
201502 | 0.223 | 99.032 | 0.291 |
201505 | 0.265 | 100.333 | 0.342 |
201508 | 0.110 | 100.548 | 0.142 |
201511 | 0.253 | 100.135 | 0.327 |
201602 | 0.320 | 100.040 | 0.414 |
201605 | 0.408 | 101.355 | 0.521 |
201608 | 0.190 | 101.617 | 0.242 |
201611 | 0.366 | 101.829 | 0.465 |
201702 | 0.376 | 102.779 | 0.473 |
201705 | 0.496 | 103.256 | 0.622 |
201708 | 0.069 | 103.587 | 0.086 |
201711 | 0.253 | 104.072 | 0.315 |
201802 | 0.070 | 105.052 | 0.086 |
201805 | 0.619 | 106.148 | 0.755 |
201808 | -0.256 | 106.383 | -0.311 |
201811 | 0.326 | 106.338 | 0.397 |
201902 | 0.199 | 106.649 | 0.241 |
201905 | 0.644 | 108.048 | 0.771 |
201908 | -0.214 | 108.245 | -0.256 |
201911 | 0.082 | 108.519 | 0.098 |
202002 | -0.515 | 109.139 | -0.611 |
202005 | 0.063 | 108.175 | 0.075 |
202008 | -0.190 | 109.662 | -0.224 |
202011 | 0.263 | 109.793 | 0.310 |
202102 | 0.117 | 110.968 | 0.136 |
202105 | 0.301 | 113.576 | 0.343 |
202108 | -0.256 | 115.421 | -0.287 |
202111 | 0.021 | 117.269 | 0.023 |
202202 | -0.253 | 119.703 | -0.274 |
202205 | 0.192 | 123.323 | 0.201 |
202208 | -0.664 | 124.958 | -0.688 |
202211 | 0.171 | 125.607 | 0.176 |
202302 | 0.004 | 126.928 | 0.004 |
202305 | 0.376 | 128.314 | 0.379 |
202308 | -0.668 | 129.538 | -0.667 |
202311 | 0.117 | 129.548 | 0.117 |
202402 | -0.407 | 129.419 | -0.407 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of AngioDynamics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Lorinda Burgess | director | 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093 |
Karen A Licitra | director | C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050 |
Michael E Tarnoff | director | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Scott Centea | officer: SVP/GM, VIT | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Dave Helsel | officer: SVP Global Operations and R&D | 400 WOOD ROAD, BRAINTREE MA 02184 |
Laura Piccinini | officer: SVP International | C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Stephen A Trowbridge | officer: SVP and General Counsel | 14 PLAZA DRIVE, LATHAM NY 120110 |
James C Clemmer | director, officer: President and CEO | COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
Wesley Johnson | director | |
Chad Thomas Campbell | officer: SVP/GM, Vascular Access | 140 POKANOKET PATH, WRENTHAM MA 02093 |
Warren Jr Nighan | officer: SVP Quality and Regulatory | ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Richard C Rosenzweig | officer: SVP and General Counsel | C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Kevin J Gould | director | 247 WASHINGTON STREET, DUXBURY MA 02332 |
Brent J. Boucher | officer: SVP and GM of Oncology | 14 PLAZA DRIVE, LATHAM NY 12110 |
Michael Greiner | officer: EVP and CFO | C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By Business Wire Business Wire • 04-04-2022
By Business Wire • 07-12-2023
By Business Wire Business Wire • 02-08-2022
By Business Wire • 12-21-2023
By Business Wire Business Wire • 02-28-2023
By Business Wire Business Wire • 06-20-2023
By Business Wire Business Wire • 06-08-2023
By Business Wire Business Wire • 03-08-2022
By Business Wire Business Wire • 03-14-2022
By Business Wire Business Wire • 05-16-2022